Details
Category: Volume 10 Issue 06 June 2022
Hits: 592

Title: Immunohistochemical expression of Her2-neu and Ki-67 in premalignant and malignant lesion of gall bladder and its correlation with survival time

Authors: Ajay Kr. Singh, Vivek Chaudhary, Madhumati Goel, Vijay Kumar

 DOI: https://dx.doi.org/10.18535/jmscr/v10i6.07

Abstract

Introduction: Gall Bladder Carcinoma (GBC) is a diagnostic and a therapeutic challenge. Although it is increasing, chronic cholecystitis remains the most worldwide gall bladder lesions, harbouring many epithelial changes that may end in carcinoma.

Aim: To investigate the expression of HER2-neu and Ki-67 in malignant and non-malignant gall bladder lesions, and to evaluate its correlation with survival time.

Materials and Methods: In this retrospective as well prospective study include total of 154 cases of gall bladder in which 85 cases of malignant lesions and 47 cases of premalignant and premalignant like lesion  (including dysplasia , metaplasia and xanthogranulomatous cholecystitis) along with 22 cases of chronic cholecystitis as control. The blocks were collected from the Department of Pathology of KGMU, Lucknow.  Immunohistochemical staining results of HER2-neu and Ki-67 were analysed and correlated by Statistical Package for the Social Sciences (SPSS) version 15 and Chi-square test and for survival time interpretation use Kaplan-Meier survival curve and Log- rank test.

Results:  Positive HER2-neu expression (+2, +3) was detected in 47.5% (19/40) of malignant cases and 12.5% (1/8) of dyspastic group, at the same time it was completely absent in the metaplastic and cholecystitis cases. Similarly Ki-67 Li expression was observed to be <10% in 75.3% of malignant and all the cases in premalignant and control groups. In malignant group, a total of 14 (16.5%) patients had Ki-67 Li expression in range 10-25% and remaining 7 (8.2%) had Ki-67 Li expression >25%.

Conclusion: HER2-neu, and Ki-67 are overexpressed in GBC cases compared with control and dysplastic group, these can be use as new therapeutic targetd agent in GBC.

Keywords:  Gall bladder cancer, Her2neu expression,  Ki-67, Chronic cholecystitis.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424
  2. Shukla VK, Khandelwal C, Roy SK, Vaidya MP. Primary carcinoma of the gall bladder: a review of a 16-year period at the University Hospital. J Surg Oncol.1985; 28(1):32-5.
  3. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA: Cancer J Clin. 2001;51(6):349–64.
  4. The Globocan Cancer Observatory. Available from: http://gco.iarc.fr/today/data /factsheets/cancers/39- All-cancers-fact-sheet.pdf. [Last accessed on 2019 Apr 10].
  5. Pragya Jain , Surbhi Goyal , Geeta Chauhan , Kaushik Majumdar et al. HER-2/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target. IJPM 2020;20(3) 214-220.
  6. CAP guidelines. Available from: https://documents.cap.org/protocols/cp-gastric-HER2biomarker17-1001. [Last accessed on 2019 Apr 10].
  7. Pujani M, Makker I, Makker A, Jetley S, Goel MM. Expression of human epidermal growth factor receptor (Her 2/neu) and proliferative marker Ki-67: Association with clinicopathological parameters in gallbladder carcinoma. Asian Pac J Cancer Prev 2016;17:3903-9.
  8. Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and C-erbB-2 expression in gallbladder cancer in Indian patients. BMC Cancer. 2006;6:126
  9. Doval DC , Azam S , Sinha R , Batra U , Mehta A. Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase 2, cyclin D1, human epidermal receptor2 and Ki67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma. J Carcinog. 2014;13:10.
  10. Serra I, Calvo A, Baez S, Yamamoto M, Endoh K, Aranda W. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer.1996;78(7):1515-7.
  11. Barreto SG,Dutt A, Chaudhary A. A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol.2014;25(6):1086–97.
  12. Sasatomi E, Tokunaga O, Miyazaki K. Precancerous conditions of gall bladder carcinoma: Overview of hitopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg.2000;7(6):556-67.
  13. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol.2005;206(3):356-65.
  14. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of Her2/neu in tumour progression and therapy. Cell Mol Life Sci.2004;61(23):2965-78.
  15. Yerushalmi R, Woods R, Ravdin PM. et al. Ki-67 in breast cancer : prognostic and predictive potential. Lancet Oncol.2010; 11:174-180.
  16. Scholzen T, Gerdes J. “ The Ki-67 protein : from the known and the unknown”. J Cell Physiol.2000 ;182(3):311-322.
  17. Kumari N, Kapoor VK, Krishnani N, Kumar K, Baitha DK. Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol. 2012 ;55(1):75-9.
  18. Schuell B , Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123
  19. Mitra AB , Murty VV, Pratap M, Sodhani P, Chaganti RS. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res. 1994;54(3):637-9.
  20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/ neu oncogene. Science. 1987;235 (4785):177-82.
  21. Roa I, de Toro G, Schalper K , de Aretxabala X , Churi C , Javle M. Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res. 2014;7(2):42-8.
  22. Yoshida H, Shimada K, Kosuge T, Hiraoka N. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. 2016;468(4):431-9.
  23. Kim YW , Huh SH, Park YK, Yoon TY, Lee SM, Hong SH. Expression of the c-erbB2 and p53 protein in gallbladder carcinomas. Oncol Rep. 2001;8(5):1127-32.
  24. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and C-erbB-2 protein expression in adenocarcinomas and epithelial dysplasia of the gall bladder. J Pathol.1993;170(1):67-72.
  25. Kim HJ, Yoo TW, Park DI, Park JH, Cho YK, Sohn CI, et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann Oncol. 2007;18(5):892–7.
  26. Wang X , Zhang J, Chen J. Result of p53, ki67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry Zhongguo Yi Xue Ke Xue Yuan  Xue  Bao. 2000 ; 22(1):57-60.
  27. Lee CS. Differences in cell proliferation and prognostic significance of proliferatingcell nuclear antigen and Ki67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer. 1996 ;78(9):1881-7.
  28. Hidalgo Grau LA , Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogues JM, Sala JS. Gall bladder carcinoma: The role of P53 protein overexpression and Ki67 antigen expression as prognostic markers. HPB (Oxford). 2004;6(3):174-80.
  29. Harder J , Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, SchmittGraeff A, Opitz OG. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol. 2009;15 (36):4511-7.

Corresponding Author

Dr Ajay Kr. Singh

Professor, Department of Pathology, King George’s Medical University (KGMU), Lucknow, UP, India